Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
35.1 HKD | -0.71% | -0.98% | -55.70% |
Jun. 01 | US lawmakers ask FBI for briefing on GenScript Biotech's links to China | RE |
May. 31 | US lawmakers ask FBI for briefing on GenScript Biotech's links to China | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-55.70% | 16.33B | - | ||
+16.73% | 121B | B+ | ||
+13.04% | 107B | B+ | ||
-5.80% | 24.82B | B+ | ||
+1.69% | 22.48B | B | ||
-10.09% | 18.32B | A- | ||
-14.00% | 15.31B | B | ||
+1.18% | 14.08B | C+ | ||
+24.18% | 11.74B | C+ | ||
+83.67% | 9.02B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603259 Stock
- 2359 Stock
- Ratings WuXi AppTec Co., Ltd.